With increased use, it is estimated that half of the patientsusing vitamin D analogues would have indication of cinacalcet for presenting PTHabove 500 pg/mL in the presence of hyperphosphatemia or hypercalcemia or for notreaching the PTH target value, between 150–300 pg/mL with the use of at least 0.1ucg/kg/dose of paricalcitol or 3 ucg/week of calcitriol or even because of having akidney transplant with PTH > 120 pg/mL, increasing from 10.5% to 25.4% ofpatients on dialysis using cinacalcet in 5 years4. The gene discussed is PTH; the disease is Hypercalcemia.